Search results for: IgG
#35045328 2022/01/16 To Up
Co-administration of rotavirus nanospheres VP6 and NSP4 proteins enhanced the anti-NSP4 humoral responses in immunized mice.Inconveniences associated with the efficacy and safety of the World Health Organization (WHO) approved/prequalified live attenuated rotavirus (RV) vaccines, sounded for finding alternative non-replicating modals and proper RV antigens (Ags). Herein, we report the development of a RV candidate vaccine based on the combination of RV VP6 nanospheres (S) and NSP4 proteins (VP6SÂ +Â NSP4). Self-assembled VP6S protein was produced in insect cells. Analyses by western blotting and transmission electron microscopy (TEM) indicated expression of VP6 trimer structures with sizes of â¥140Â kDa and presence of VP6S. Four group of mice were immunized (2-dose formulation) intra-peritoneally (IP) by eitherÂ¨VP6SÂ +Â NSP4Â¨ or each protein alone (VP6S or NSP4) emulsified in aluminium hydroxide or control. Results indicated that VP6SÂ +Â NSP4 formulation induced significant anti-VP6 IgG (PÂ <Â 0.001) and IgA (PÂ <Â 0.05) as well as anti-NSP4 IgG (PÂ <Â 0.001) and enhancement of protective immunity. Analyses of anti-VP6S and anti-NSP4 IgG subclass (IgG1 and IgG2a) showed IgG1/IgG2a â¥6 and IgG1/IgG2a â¥3 ratios, respectively indicating Th2 polarization of immune responses. The combination of VP6SÂ +Â NSP4 proteins emulsified in aluminum hydroxide adjuvant might present a dual universal, efficient and cost-effective candidate vaccine against RV infection.
Atefeh Afchangi, Somayeh Jalilvand, Arash Arashkia, Tayebeh Latifi, Mohammad Farahmand, Maryam Mashhadi Abolghasem Shirazi, Seyed Dawood Mousavi Nasab, Sayed Mahdi Marashi, Farzin Roohvand, Zabihollah Shoja
1378 related Products with: Co-administration of rotavirus nanospheres VP6 and NSP4 proteins enhanced the anti-NSP4 humoral responses in immunized mice.25mg100 μg1mg1mg1 mg100 μg100ug Lyophilized
#35044938 2021/12/31 To Up
COVID-19 in Malaysia: exposure assessment and prevention practices among healthcare workers at a teaching hospital.During the second wave of the coronavirus disease 19 (COVID-19) pandemic, Malaysia reported several COVID-19 clusters related to healthcare workers. Thus, addressing and understanding the risk of exposure in healthcare workers is important to prevent future infection and reduce secondary COVID-19 transmission within the healthcare settings. In this study, we aim to assess exposure and prevention practices against COVID-19 among healthcare workers at the Hospital Canselor Tuanku Muhriz, a university teaching hospital based in Kuala Lumpur, Malaysia.
Nor Azila Muhammad Azami, Nor Azian Abdul Murad, Azmawati Mohammed Nawi, Sharifah Azura Salleh, Petrick Periyasamy, Najma Kori, Mohd Rohaizat Hasan, Norfazilah Ahmad, Anita Sulong, Hanita Othman, Tuti Ningseh Mohd Don, Nurul Syakima Ab Mutalib, Ezanee Azlina Mohamad Hanif, Siti Aishah Sulaiman, Nurul Syeefa' Zulkiflee, Abdul Rashid Abdul Kader, Abdul Halim Abdul Gafor, Hanafiah Haruna Rashid, Rahman Jamal
2501 related Products with: COVID-19 in Malaysia: exposure assessment and prevention practices among healthcare workers at a teaching hospital.20 100 μg1 Set1 Set20 100 μg100 µl (2 mM)100 μg5 mg100 μg4 Membranes/Box5 mg
Error loading info... Pleas try again later.
#35044502 2022/01/19 To Up
Asymptomatic SARS-CoV-2 seropositivity: patients with childhood-onset rheumatic diseases versus healthy children.We aimed to find out the asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence among pediatric patients with rheumatic diseases and healthy children and to compare them with each other.
Fatih Haslak, Dogukan Ozbey, Mehmet Yildiz, Amra Adrovic, Sezgin Sahin, Oya Koker, Ayten Aliyeva, Vafa Guliyeva, Gamze Yalcin, Gulmelek Inanli, Bekir S Kocazeybek, Ozgur Kasapcopur, Kenan Barut
1141 related Products with: Asymptomatic SARS-CoV-2 seropositivity: patients with childhood-onset rheumatic diseases versus healthy children.200ul 1 G200ul2.5 mg5 g25 mg 25 G 5 MG 100 G2500 unit250ul250ul
No related Items
#35044205 2022/01/19 To Up
Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2.To fight severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), mass vaccination has begun in many countries. To investigate the usefulness of a serological assay to predict vaccine efficacy, we analyzed the levels of IgG, IgM, and IgA against the receptor-binding domain (RBD) of SARS-CoV-2 in the sera from BNT162b2 vaccinated individuals in Japan. This study included 219 individuals who received two doses of BNT162b2. The levels of IgG, IgM, and IgA against RBD were measured by enzyme-linked immunosorbent assay before and after the first and second vaccination, respectively. The relationship between antibody levels and several factors, including age, gender, and hypertension were analyzed. Virus-neutralizing activity in sera was measured to determine the correlation with the levels of antibodies. A chemiluminescent enzyme immunoassay (CLEIA) method to measure IgG against RBD was developed and validated for the clinical setting. The levels of all antibody isotypes were increased after vaccination. Among them, RBD-IgG was dramatically increased after the second vaccination. The IgG levels in females were significantly higher than in males. There was a negative correlation between age and IgG levels in males. The IgG levels significantly correlated with the neutralizing activity. The CLEIA assay measuring IgG against RBD showed a reliable performance and a high correlation with neutralizing activity. Monitoring of IgG against RBD is a powerful tool to predict the efficacy of SARS-CoV-2 vaccination and provides useful information in considering a personalized vaccination strategy for COVID-19. Mass vaccination campaigns using mRNA vaccines against SARS-CoV-2 have begun in many countries. Serological assays to detect antibody production may be a useful tool to monitor the efficacy of SARS-CoV-2 vaccination in individuals. Here, we reported the induction of antibody isotype responses after the first and second dose of the BNT162b2 vaccine in a well-defined cohort of employees in Japan. We also reported that age, gender, and hypertension are associated with differences in antibody response after vaccination. This study not only provides valuable information with respect to antibody responses after BNT162b2 vaccination in the Japanese population but also the usefulness of serological assays for monitoring vaccine efficacy in clinical laboratories to determine a personalized vaccination strategy for COVID-19.
Hidetsugu Fujigaki, Yasuko Yamamoto, Takenao Koseki, Sumi Banno, Tatsuya Ando, Hiroyasu Ito, Takashi Fujita, Hiroyuki Naruse, Tadayoshi Hata, Saya Moriyama, Yoshimasa Takahashi, Tadaki Suzuki, Takahiro Murakami, Yukihiro Yoshida, Yo Yagura, Takayoshi Oyamada, Masao Takemura, Masashi Kondo, Mitsunaga Iwata, Kuniaki Saito
2613 related Products with: Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2.100 ug200 ug200 ug1 mg100 ug100 ug200 ug200 ug100 ug
#35043790 2022/01/19 To Up
Detection of multiply charged protein ions using matrix-assisted laser desorption/ionization mass spectrometry and a force-dried droplet method with a 2-nitrophloroglucinol matrix.Conventional dried droplet (DD) methods show poor reproducibility in matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) due to the frequent induction of a heterogeneous sample distribution. Recently, a forced dried droplet (FDD) sample preparation method was introduced to form homogeneous samples; this method improves the reproducibility of MALDI-MS analysis and generates highly multiply charged ions compared to DD methods. The FDD method utilizes secondary nucleation to generate a homogeneous sample distribution by applying an external force such as fluid shear stress by stirring the sample using a micropipette tip. In this study, a 2-nitrophloroglucinol (2-NPG) matrix was used for the DD and FDD sample preparation methods, and the charge state and homogeneity were compared by detecting multiply charged ions of proteins including cytochrome , myoglobin, and immunoglobulin G (IgG) and measuring the relative standard deviation (RSD). FDD with a 2-NPG matrix produced a more homogeneous sample distribution and higher charge state ions than the DD method. FDD with a 2-NPG matrix was applied in MALDI-MS analysis of IgG fragments obtained from sequential reduction of IgG. In addition, FDD with intentional scratching of the MALDI plate by rotating a micropipette tip was found to provide similar or better reproducibility, higher charge state ions, and more uniformly distributed sample morphology compared to FDD without scratching.
Kangseok Yun, Iqbal Jalaludin, Shinhee Jung, Kyoung-Soon Jang, Jeongkwon Kim
1891 related Products with: Detection of multiply charged protein ions using matrix-assisted laser desorption/ionization mass spectrometry and a force-dried droplet method with a 2-nitrophloroglucinol matrix.1 mL0.2 mg2 ml200 100 1 ml0.1ml (1mg/ml)250tests100tests100tests1 ml
Error loading info... Pleas try again later.
#35043108 2022/01/11 To Up
A single dose ChAdOx1 nCoV-19 vaccine elicits high antibody responses in individuals with prior SARS-CoV-2 infection comparable to that of double dose vaccinated SARS-CoV-2 infection naÃ¯ve individuals.Background A single dose COVID-19 vaccines, mostly mRNA-based vaccines, are shown to induce robust antibody responses in individuals who were previously infected with SARS-CoV-2, suggesting the sufficiency of a single dose to those individuals. However, these important data are limited to developed nations and lacking in resource-limited countries, like Ethiopia. Methods We compared receptor-binding domain (RBD)-specific IgG antibodies in 40 SARS-CoV-2 naÃ¯ve participants and 25 participants previously infected with SARS-CoV-2, who received two doses of ChAdOx1 nCoV-19 vaccine. We measured the antibody response in post-vaccination blood samples from both groups of participants collected at four different post-vaccination time points: 8- and 12-weeks after each dose of the vaccine administration using an in-house developed ELISA. Results We observed a high level of anti-RBD IgG antibodies titers 8-weeks after a single dose administration (16/27; 59.3%) among naÃ¯ve participants, albeit dropped significantly (p<0.05) two months later, suggesting the protective immunity elicited by the first dose ChAdOx1 nCoV-19 vaccine will likely last for a minimum of three months. However, as expected, a significant (p<0.001) increase in the level of anti-RBD IgG antibodies titers was observed after the second dose administration in all naÃ¯ve participants. By contrast, the ChAdOx1 nCoV-19 vaccine-induced anti-RBD IgG antibody titers produced by the P.I participants at 8- to 12-weeks post-single dose vaccination were found to be similar to the antibody titers seen after a two-dose vaccination course among infection- naÃ¯ve participants and showed no significant (p>0.05) increment following the second dose administration. Conclusion Taken together, our findings show that a single ChAdOx1 nCoV-19 dose in previously SARS-CoV-2 infected individuals elicits similar antibody responses to that of double dose vaccinated naÃ¯ve individuals. Age and sex were not associated with the level of vaccine-elicited immune responses in both individuals with and without prior SARS-CoV-2 infection. Further studies are required to assess the need for a booster dose to extend the duration and amplitude of the specific protective immune response in Ethiopia settings, especially following the Omicron pandemic.
Tesfaye Gelanew, Andargachew Mulu, Markos Abebe, Timothy A Bates, Liya Wassie, Mekonnen Tefer, Desalegn Fentahun, Aynalem Alemu, Frehiwot Tamiru, Gebeyehu Assefa, Abebe Genetu Bayih, Fikadu G Taffesse, Adane Mihret, Alemseged Abdissa
2788 related Products with: A single dose ChAdOx1 nCoV-19 vaccine elicits high antibody responses in individuals with prior SARS-CoV-2 infection comparable to that of double dose vaccinated SARS-CoV-2 infection naÃ¯ve individuals.200ul100ug Lyophilized200ul200ul200ul100ug Lyophilized100ug Lyophilized100ug Lyophilized200ul250 m Pcs Per Pack200ul200ul
#35043093 2022/01/14 To Up
Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial.Lipid nanoparticle (LNP) encapsulated self-amplifying RNA (saRNA) is a novel technology formulated as a low dose vaccine against COVID-19.
Katrina M Pollock, Hannah M Cheeseman, Alexander J Szubert, Vincenzo Libri, Marta Boffito, David Owen, Henry Bern, Jessica O'Hara, Leon R McFarlane, Nana-Marie Lemm, Paul F McKay, Tommy Rampling, Yee Ting N Yim, Ana Milinkovic, Cherry Kingsley, Tom Cole, Susanne Fagerbrink, Marites Aban, Maniola Tanaka, Savviz Mehdipour, Alexander Robbins, William Budd, Saul N Faust, Hana Hassanin, Catherine A Cosgrove, Alan Winston, Sarah Fidler, David T Dunn, Sheena McCormack, Robin J Shattock,
1539 related Products with: Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial.100ug1 g96 wells (1 kit)100ul200ul200ul10 mg1000 100 mg 25 MG200ug
#35042847 2022/01/18 To Up
Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients.Understanding antibody-based SARS-CoV-2 immunity in hematologic malignancy (HM) patients following infection is crucial to inform vaccination strategies for this highly vulnerable population. This cross-sectional study documents the anti-SARS-CoV-2 humoral response and serum neutralizing activity in 189 HM patients recovering from a PCR-confirmed infection. The overall seroconversion rate was 85.7%, with the lowest values in patients with lymphoid malignancies or undergoing chemotherapy. Therapy-naive patients in the "watch and wait" status were more likely to seroconvert and display increased anti-s IgG titers. Enhanced serum neutralizing activity was observed in the following SARS-CoV-2-infected HM patient groups: (i) males; (ii) severe COVID-19; and (iii) "watch and wait" or "complete/partial response". The geometric mean (GeoMean) ID50 neutralization titers in patients analyzed before or after 6 months post-infection were 299.1 and 306.3, respectively, indicating that >50% of the patients in either group had a neutralization titer sufficient to provide 50% protection from symptomatic COVID-19. Altogether, our findings suggest that therapy-naive HM patients mount a far more robust immune response to SARS-CoV-2 infection vs. patients receiving anti-cancer treatment, raising the important question as to whether HM patients should be vaccinated before therapy and/or receive vaccine formats capable of better recapitulating the natural infection.
Cinzia Borgogna, Riccardo Bruna, Gloria Griffante, Licia Martuscelli, Marco De Andrea, Daniela Ferrante, Andrea Patriarca, Abdurraouf Mokhtar Mahmoud, Valentina Gaidano, Monia Marchetti, Davide Rapezzi, Michele Lai, Mauro Pistello, Marco Ladetto, Massimo Massaia, Gianluca Gaidano, Marisa Gariglio
1178 related Products with: Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients.100 UG100ug Lyophilized
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
Schweiz Züri +41435006251
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
GENTAUR Nederland BV
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
53 Iskar Str. 1191 Kokalyane, Sofia